Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALXN2230 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Participants will be enrolled across multiple cohorts and will receive a single dose of placebo. |
| ALXN2230 | EXPERIMENTAL | Participants will be enrolled across multiple cohorts and will receive a single dose of ALXN2230. |
| Name | Type | Description |
|---|---|---|
| ALXN2230 | DRUG | Participants will receive ALXN2230 via SC injection. Optional cohort will receive ALXN2230 via SC infusion. |
| Placebo | DRUG | Participants will receive placebo via SC injection. Optional cohort will receive placebo via SC infusion. |
Inclusion Criteria: * Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. * Baseline immunoglobulin G (IgG) concentrations ≥ 1000 milligrams per deciliter (mg/dL) and ≤ 1600 mg/dL at Scre...
ALXN2230 is an investigational small molecule being studied in healthy adult participants. It is currently in Phase 1 clinical development, and its safety, tolerability, pharmacokinetics, and pharmacodynamics are being evaluated in a clinical trial.
ALXN2230 is being developed by AstraZeneca PLC, which is listed on the stock exchange under the ticker symbol AZN. The company is conducting a Phase 1 clinical trial to evaluate the drug in healthy participants.
ALXN2230 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 study is currently recruiting participants to assess its safety and tolerability.
ALXN2230 is being studied in a Phase 1 clinical trial with the identifier NCT07352423. This randomized, double-blind, placebo-controlled study is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALXN2230 in healthy adult participants in the United Kingdom.
ALXN2230 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The ongoing trial is designed to evaluate its safety and tolerability in healthy participants, and it has not yet been studied in patients with any disease.